Leap Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Leap Therapeutics has a total shareholder equity of $65.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $81.4M and $15.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$78.48m |
| Equity | US$65.79m |
| Total liabilities | US$15.64m |
| Total assets | US$81.43m |
Recent financial health updates
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?
Mar 13
Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?
Nov 22Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation
May 01We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely
Jan 04Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?
Sep 15Recent updates
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?
Mar 13Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?
Nov 22Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05
Aug 12Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers
Jul 12Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022
Jun 27Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation
May 01Leap Therapeutics: Waiting For One More Leap
Feb 18We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely
Jan 04Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?
Nov 29Leap Therapeutics: All On The Line
Oct 13Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?
Sep 15Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?
Jun 01Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth
Mar 03Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?
Jan 27
Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year
Dec 23Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)
Nov 18Financial Position Analysis
Short Term Liabilities: LPTX's short term assets ($79.6M) exceed its short term liabilities ($15.6M).
Long Term Liabilities: LPTX's short term assets ($79.6M) exceed its long term liabilities ($39.0K).
Debt to Equity History and Analysis
Debt Level: LPTX is debt free.
Reducing Debt: LPTX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LPTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LPTX has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 14.6% each year.